Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03633799 · ClinicalTrials.gov registry record · Phase 3

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

A Phase 3 study of Women at Risk for Pregnancy, sponsored by Sebela Women's Health.

Active
Registry status
Phase 3
Development phase
1,620
Enrollment target
20
Study locations

NCT03633799 is a Phase 3 study of Women at Risk for Pregnancy that is active but no longer recruiting, run by Sebela Women's Health. The registered enrollment target is 1,620 participants. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03633799, a Phase 3 study of Women at Risk for Pregnancy, is active but no longer recruiting, sponsored by Sebela Women's Health.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,620 participants
Enrollment target
20
Study locations

Study Summary

To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept

Interventions

  • DRUG VeraCept

Study Locations (20)

California

  • Essential Access Health - Berkeley
  • Essential Access Health - Los Angeles
  • Empire Clinical Research - Pomona
  • University of California, Davis Health System - Sacramento
  • M3 Wake Research (formerly Women's Health Care Research) - San Diego
  • M3 Wake Research (formerly Medical Center for Clinical Research) - San Diego
  • Stanford University, Medical Center, Obstetrics and Gynecolocy - Stanford

Arizona

  • MomDoc Women's Health Research - Scottsdale
  • Copperstate OB/GYN Associates - Tucson

Georgia

  • Emory University School of Medicine - Atlanta
  • Soapstone Center for Clinical Research - Decatur

Indiana

  • Women's Health Advantage - Fort Wayne
  • Indiana University - Indianapolis

Colorado

  • Velocity Clinical Research (formerly Downtown Women's Health Care) - Englewood

Florida

  • Altus Research, Inc - Lake Worth

Idaho

  • Clinical Research Prime - Idaho Falls

Louisiana

  • Praetorian Pharmaceutical Research - Marrero

Trial Details

FieldValue
Enrollment Target 1,620 participants
Start Date 2018-08-22
Est. Completion 2027-09-22
Phase Phase 3

Sponsor

Sebela Women's Health

5 total trials

What the Registry Record Tells You About NCT03633799

The ClinicalTrials.gov registry entry for NCT03633799 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sebela Women's Health, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Women at Risk for Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which VeraCept is the first listed.

NCT03633799 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Georgia.

Frequently Asked Questions

What is clinical trial NCT03633799 about?

NCT03633799 is a clinical study titled "Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS". To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept

What is the current status of trial NCT03633799?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,620 participants. The study started on 2018-08-22. Estimated completion is 2027-09-22.

What conditions does trial NCT03633799 study?

This clinical trial studies the following conditions: Women at Risk for Pregnancy.

What interventions are being tested in trial NCT03633799?

The interventions under investigation include: VeraCept (DRUG).

Who is sponsoring clinical trial NCT03633799?

This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03633799 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.